Literature DB >> 21448137

Pharmacotherapy: inhibiting LV remodeling—the need for a targeted approach.

Jay N Cohn.   

Abstract

Mesh：

Substances：

Year:  2011        PMID： 21448137     DOI： 10.1038/nrcardio.2011.48

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN： 1759-5002            Impact factor:   32.419


× No keyword cloud information.
  10 in total

1.  Combination of isosorbide dinitrate and hydralazine in blacks with heart failure.

Authors:  Anne L Taylor; Susan Ziesche; Clyde Yancy; Peter Carson; Ralph D'Agostino; Keith Ferdinand; Malcolm Taylor; Kirkwood Adams; Michael Sabolinski; Manuel Worcel; Jay N Cohn
Journal:  N Engl J Med       Date:  2004-11-08       Impact factor: 91.245

2.  Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction.

Authors:  Scott D Solomon; Sung Hee Shin; Amil Shah; Hicham Skali; Akshay Desai; Lars Kober; Aldo P Maggioni; Jean L Rouleau; Roxzana Y Kelly; Allen Hester; John J V McMurray; Marc A Pfeffer
Journal:  Eur Heart J       Date:  2011-02-10       Impact factor: 29.983

3.  Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition.

Authors:  K M McDonald; P F Carlyle; J Matthews; K Hauer; T Elbers; D Hunter; J N Cohn
Journal:  Trans Assoc Am Physicians       Date:  1990

4.  Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients.

Authors:  Alan H Gradman; Roland E Schmieder; Robert L Lins; Juerg Nussberger; Yanntong Chiang; Martin P Bedigian
Journal:  Circulation       Date:  2005-02-21       Impact factor: 29.690

5.  Early prevention of left ventricular dysfunction after myocardial infarction with angiotensin-converting-enzyme inhibition.

Authors:  N Sharpe; H Smith; J Murphy; S Greaves; H Hart; G Gamble
Journal:  Lancet       Date:  1991-04-13       Impact factor: 79.321

6.  Effect of valsartan added to background ACE inhibitor therapy in patients with heart failure: results from Val-HeFT.

Authors:  Henry Krum; Peter Carson; Csaba Farsang; Aldo P Maggioni; Robert D Glazer; Nora Aknay; Yann-Tong Chiang; Jay N Cohn
Journal:  Eur J Heart Fail       Date:  2004-12       Impact factor: 15.534

7.  Immediate administration of mineralocorticoid receptor antagonist spironolactone prevents post-infarct left ventricular remodeling associated with suppression of a marker of myocardial collagen synthesis in patients with first anterior acute myocardial infarction.

Authors:  Masaru Hayashi; Takayoshi Tsutamoto; Atsuyuki Wada; Takashi Tsutsui; Chitose Ishii; Keijin Ohno; Masanori Fujii; Atsushi Taniguchi; Tomokazu Hamatani; Yoshitaka Nozato; Ken Kataoka; Naoki Morigami; Masato Ohnishi; Masahiko Kinoshita; Minoru Horie
Journal:  Circulation       Date:  2003-05-05       Impact factor: 29.690

8.  Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators.

Authors:  M A Pfeffer; E Braunwald; L A Moyé; L Basta; E J Brown; T E Cuddy; B R Davis; E M Geltman; S Goldman; G C Flaker
Journal:  N Engl J Med       Date:  1992-09-03       Impact factor: 91.245

Review 9.  Cardiac remodeling--concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling.

Authors:  J N Cohn; R Ferrari; N Sharpe
Journal:  J Am Coll Cardiol       Date:  2000-03-01       Impact factor: 24.094

10.  Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.

Authors:  M St John Sutton; M A Pfeffer; T Plappert; J L Rouleau; L A Moyé; G R Dagenais; G A Lamas; M Klein; B Sussex; S Goldman
Journal:  Circulation       Date:  1994-01       Impact factor: 29.690
  10 in total
  4 in total

Review 1.  Reverse remodeling in heart failure--mechanisms and therapeutic opportunities.

Authors:  Norimichi Koitabashi; David A Kass
Journal:  Nat Rev Cardiol       Date:  2011-12-06       Impact factor: 32.419

Review 2.  Cardiac remodeling at the population level--risk factors, screening, and outcomes.

Authors:  Ola Gjesdal; David A Bluemke; Joao A Lima
Journal:  Nat Rev Cardiol       Date:  2011-10-25       Impact factor: 32.419

Review 3.  Cardiac Imaging in Heart Failure with Comorbidities.

Authors:  Chiew Wong; Sylvia Chen; Pupalan Iyngkaran
Journal:  Curr Cardiol Rev       Date:  2017

Review 4.  Pharmacological Modulation of Cardiac Remodeling after Myocardial Infarction.

Authors:  Wei Zhao; Jia Zhao; Jianhui Rong
Journal:  Oxid Med Cell Longev       Date:  2020-12-30       Impact factor: 6.543
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.